A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis

NCT04399837 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

123

Enrollment

INDUSTRY

Sponsor class

Conditions

Generalized Pustular Psoriasis

Interventions

DRUG: Spesolimab
DRUG: Placebo

Sponsor

Boehringer Ingelheim